about
Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosisAchievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function.Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 DiabetesLack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of type 1 diabetesPrevention of type 1 diabetes: the time has come.Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitusUse of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries.Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.Characterization of residual β cell function in long-standing type 1 diabetes.The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration.Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.Pramlintide but not Liraglutide suppresses meal-stimulated glucagon responses in type 1 diabetes.Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.No Summer Vacation From Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year.Closing the Loop on Managing Youth With Type 1 Diabetes: Children Are Not Just Small AdultsISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologiesDiabetes types 1 and 2 in the pediatric populationDiabetes: Insulin pumps in children with T1DM--we told you soConnecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes
P50
Q33646636-5B72120C-C215-4225-9C6D-AC26B5D4A1FFQ35841231-D21B4D39-C7D3-4644-ACB7-C27BB4C8AF81Q36726160-CB684A9C-9595-46A2-B820-1F87E3659C52Q36868102-906CFE52-E093-43F3-9B58-6D2008418735Q37150732-688E94FD-26B3-4837-9DF4-F75005E1BD46Q37381456-684979EC-A13A-4101-A12F-3E9A43FAADC3Q40347021-542DB8D0-5EC3-43CE-AF40-D71E62960B0BQ42008289-86750C8D-2B16-4719-8F81-B9057B1920A9Q45384613-B92B07AC-D999-4A4F-A81E-4FD905E362D4Q46215789-150AEEBD-57C2-44EF-B88B-046A2E6F7897Q47738149-B3D76660-1A5B-4F42-858F-94B1442B6D5DQ50042259-A0E357D1-86A7-4110-822E-E216A5CE232DQ50049206-9423263F-B928-45A7-B042-3DB388156857Q50643784-8CF7D8F4-FE4E-43D7-8879-BFFE521715C7Q51782163-FD80C604-5BE3-4FA4-AA75-31C84115DE4AQ57171958-0E9EEAEF-E76B-49EC-BB5E-6D9F12DE1A7EQ57210019-73FCC3F3-B978-41F7-8772-7581ACA858D9Q83386360-7C71844E-B296-47D3-812E-199581381056Q86067459-8E45FA02-18DE-47E2-8134-07DC5BA0376CQ91759970-6287A825-D870-4FF6-A959-03862A97C784
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jennifer L Sherr
@ast
Jennifer L Sherr
@en
Jennifer L Sherr
@es
Jennifer L Sherr
@nl
type
label
Jennifer L Sherr
@ast
Jennifer L Sherr
@en
Jennifer L Sherr
@es
Jennifer L Sherr
@nl
prefLabel
Jennifer L Sherr
@ast
Jennifer L Sherr
@en
Jennifer L Sherr
@es
Jennifer L Sherr
@nl
P106
P1153
16426455500
P21
P31
P496
0000-0001-9301-3043